Patients With Moderate-to-Severe Ulcerative Colitis May Find Significant Relief as New Treatment Option Shows Good Results in Clinical Trial
A phase 2 trial of a monoclonal antibody known as tulisokibart for moderate-to-severe ulcerative colitis (UC) showed promising results for those who have not responded to conventional inflammatory bowel disease (IBD) treatment. The results were...
25-Sep-2024 5:05 PM EDT
Add to Favorites